Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Aetna Endolymphatic Hydrops Tests Coverage | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0571

    Endolymphatic Hydrops (Meniere's Disease) Tests

    Customize your policy alerts

    Sign up for Aetna Policy 0571 alerts

    Get alerted when Policy 0571 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity and investigational determinations for diagnostic tests used to evaluate endolymphatic hydrops (Meniere's disease), and lists related policies and applicable billing codes; applies to Aetna members and their providers.

    Policy Summary
    PayerAetna
    PolicyEndolymphatic Hydrops (Meniere's Disease) Tests
    Policy CodePolicy 0571
    Change TypeNo material changes
    Effective DateNov 9, 2001
    Last ReviewAug 11, 2023
    Next Review DateJun 13, 2024
    Key ActionObtain and document baseline and repeat audiometry when ordering dehydration (glycerol/urea) testing and limit dehydration testing to atypical presentations of Meniere's disease.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1medically necessary indication
    10+experimental/investigational tests
    92517-92519,92550,92567,92584,81406example codes
    47.6% / 83.8%ECoG performance (sens/spec)

    Coverage Criteria for Diagnostic Tests for Endolymphatic Hydrops (Meniere's Disease)

    Medically necessary indication

    Covered when ALL of the following are met

    Dehydration testing (glycerol/urea/other osmotic diuretics): Dehydration testing to verify the suspicion of endolymphatic hydrops (Meniere's disease) is medically necessary only in members with atypical presentations of this disease.See test criteria below (repeat audiometry: ≥10 dB improvement at ≥2 frequencies [250–2,000 Hz] OR ≥12% improvement in speech discrimination).

    Test protocol includes baseline audiometry and repeat audiometry post-ingestion (commonly at ~3 hours); consider side effects (headache, nausea, thirst, diarrhea, emesis, diuresis, dizziness).

    Experimental / Investigational

    Not covered / Experimental and Investigational

    Listed tests considered experimental/investigational: The following are considered experimental and investigational because their effectiveness for these indications has not been established: endolymphatic sac immunohistochemistry (aquaporin-2, V2R, NKCC2, TRPV4); genetic testing of KCNE1, KCNE3, SIK1, SLC8A1, SLC26A4; intravenous gadolinium inner-ear MRI for diagnosis of Meniere's disease; multi-frequency tympanometry for diagnosis; testing for antibodies against inner ear antigens; vestibular evoked myogenic potential (VEMP) for diagnosis and monitoring of Meniere disease; and video head impulse test.N/A

    These procedures are considered investigational for the indications listed in this policy and are not supported as standard diagnostic tests.

    Evidence-based coverage considerations

    Summary of available evidence and guideline stance

    Imaging (IV-Gd MRI) use conditions: Consider IV gadolinium inner-ear MRI as a supplementary diagnostic tool when the clinical diagnosis is uncertain or when atypical or secondary causes are suspected; correlate imaging findings with audiovestibular testing and document rationale. Reported sensitivity and specificity vary (example reported 69% sensitivity and 83% specificity) and results depend on timing of imaging (for example, during a vertigo attack) and technique.

    Evidence supports MRI as a supplementary test but not as a standalone definitive diagnostic; timing (e.g., during attack) and small sample sizes affect performance.

    Vestibular functional tests utility: VEMP (cVEMP/oVEMP), VHIT, and multi-frequency tympanometry have demonstrated inconsistent diagnostic performance; abnormal results may support but do not reliably establish a diagnosis of Meniere's disease.

    Tests are emerging and not standardized; use results in the context of clinical assessment.

    Electrocochleography (ECoG): Electrocochleography (SP/AP ratio) demonstrates limited sensitivity (~47.6%) and moderate specificity (~83.8%); professional guidelines recommend clinicians should not routinely order ECoG or vestibular function testing solely to establish the diagnosis of Meniere's disease.

    Aetna considers dehydration testing (glycerol, urea, or other osmotic diuretics) medically necessary only for members with atypical presentations of endolymphatic hydrops (Meniere’s disease). For indications other than atypical presentations, dehydration testing is considered experimental and investigational because its effectiveness has not been established. The test protocol includes baseline audiometry and repeat audiometry after administration of the osmotic agent; a positive test is defined by the thresholds noted elsewhere in this policy (see definitions/thresholds).

    Hydrops-protocol MRI using intravenous gadolinium is described as a potential supplementary tool when clinical diagnosis is uncertain or atypical/secondary causes are suspected, but routine use for early or subtle symptoms is limited. The literature highlights lack of normal control cutoffs, effects of disease duration, small study sizes, variability in MRI sequence parameters and hydrops grading, and concerns about reproducibility across MRI manufacturers; these issues currently limit broader, standardized clinical application of IV‑Gd inner‑ear MRI. Documentation correlating imaging findings with audiovestibular testing and clinical rationale is recommended when used.

    Multi‑frequency tympanometry (MFT) has been evaluated as an in‑office, noninvasive test (measuring 2‑kHz probe tone Y‑width) to reflect cochlear pressure changes. In a prospective study the authors observed a high false‑positive rate, modest sensitivity (58.3%) and specificity (66.3%), and no significant differences across study groups; therefore the investigators did not support standardized use of MFT as an additional diagnostic tool for detecting endolymphatic hydrops. A negative MFT result was considered unlikely to reflect hydrops.

    To reiterate, dehydration (glycerol/urea) testing performed for indications other than atypical presentations of Meniere’s disease is considered experimental and investigational and therefore not covered. When dehydration testing is performed for atypical presentations, the established positivity criteria (repeat audiometry showing an improvement of ≥10 dB at ≥2 frequencies or ≥12% improvement in speech discrimination) should be used to interpret results.

    Guideline recommendations and systematic reviews advise against routine ordering of electrocochleography (ECoG) or vestibular function testing solely to establish a diagnosis of Meniere’s disease. These statements reflect that available tests for endolymphatic hydrops are not standardized, have variable sensitivity and specificity, and therefore should not be used routinely as definitive diagnostic tools without correlation to the clinical presentation.

    Recent clinical studies have failed to demonstrate consistent, reliable objective diagnostic performance for frequency‑specific ECoG and related measures. In a 91‑patient (182‑ear) series comparing frequency‑specific action potential latency, traveling wave times, and SP/AP ratios across diagnostic groups, no significant differences were found for AP latency or SP/AP ratio between Meniere’s classification groups, and traveling wave velocity did not prove to be a useful objective diagnostic test. Taken together, these data do not support routine use of frequency‑specific ECoG as a definitive diagnostic measure for endolymphatic hydrops.

    Coding and Diagnostic Criteria

    CPT / HCPCS codes mentionedmixed
    81406Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)
    92517Vestibular evoked myogenic potential (VEMP) testing; cervical (cVEMP)
    92518Vestibular evoked myogenic potential (VEMP) testing; ocular (oVEMP)
    92519Vestibular evoked myogenic potential (VEMP) testing; cervical and ocular
    92550Tympanometry and reflex threshold measurements [multi-frequency tympanometry]
    92567Tympanometry (impedance testing) [multi-frequency tympanometry]
    92584Electrocochleography
    69805-69806Endolymphatic sac operation
    A9579Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml
    ICD-10 codes referencedICD-10
    H81.01-H81.09Meniere's disease
    H81.10-H81.13Benign paroxysmal vertigo
    H81.311-H81.399Other peripheral vertigo
    H81.41-H81.49Vertigo (including vertigo of central origin)
    H83.01-H83.2X9Labyrinthitis
    R26.0-R26.9Abnormalities of gait and mobility
    R42Dizziness and giddiness
    Positive glycerol/dehydration test criteria
    Improvement in pure-tone thresholds>= 10 dB improvement at 2 or more frequencies (250–2,000 Hz)
    Speech discrimination improvement>= 12% improvement in speech discrimination scores
    Timing of repeat testingRepeat audiometry typically performed at ~3 hours post-ingestion (sometimes at 1 and 2 hours)
    MFT positive-test threshold (Y width)
    MFT positive-test threshold (Y width)>= 235 daPa
    Mean Y width in affected ears (de Jong et al. 2023)315.6 ± 70.2 daPa

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Recommended for IV-Gd Inner-Ear MRI

    Prior authorization is recommended for intravenous gadolinium (IV-Gd) inner-ear MRI when used to evaluate suspected endolymphatic hydrops (Meniere's disease). When requesting advanced imaging, document the audiovestibular correlation and the clinical rationale for why IV-Gd MRI is needed to supplement the evaluation rather than routine testing.

    • Affected service: IV-Gd inner-ear MRI (contrast agent A9579 may be billed).
    • Include in imaging request: clinical history, audiometric and vestibular test results, and specific rationale linking MRI findings to management decisions.
    Documentation Required

    Dehydration Testing — Medically Necessary Only for Atypical Presentations

    Dehydration (glycerol/urea/other osmotic diuretic) testing is considered medically necessary only for patients with atypical presentations of endolymphatic hydrops (Meniere's disease). For other indications, dehydration testing is considered experimental and investigational and is not supported by evidence.

    Background and Rationale

    Endolymphatic hydrops (Meniere's disease) is a clinical syndrome characterized by episodic vertigo, fluctuating sensorineural hearing loss (often low‑frequency), tinnitus, and aural fullness. Diagnostic testing options described in the literature include dehydration (glycerol/urea) testing, electrocochleography, vestibular tests (VEMP, VHIT), IV‑Gd inner‑ear MRI, and multi‑frequency tympanometry; however, many of these tests lack standardization, have variable sensitivity/specificity, and are best used to supplement—rather than replace—careful clinical assessment. When advanced tests such as IV‑Gd MRI are used, results should be interpreted in the context of clinical findings and audiovestibular testing due to limitations related to technique, timing, and reproducibility.

    Definitions and Test Descriptions

    Positive glycerol/dehydration test — formal definition
    Primary criterion>= 10 dB improvement at 2 or more frequencies (250–2,000 Hz)
    Alternate criterion>= 12% improvement in speech discrimination
    Clinical contextUsed after baseline audiometry and administration of glycerol, urea, or other osmotic diuretic
    VEMP — definition and role (cVEMP and oVEMP)
    DefinitionVestibular evoked myogenic potential (VEMP) — a test assessing otolith (saccule/utricle) function using cervical (cVEMP) and ocular (oVEMP) responses.
    cVEMP roleInhibitory sacculocollic reflex test; shows characteristic changes in symptomatic Meniere ears and may detect early saccular hydrops

    Policy Revision History

    2001-11-09effective

    Policy originally effective on 2001-11-09.

    2023-08-11last_review

    Policy last reviewed on 2023-08-11.

    2024-06-13next_reviewLatest

    Next scheduled review on 2024-06-13.

    Policy Summary
    PayerAetna
    PolicyEndolymphatic Hydrops (Meniere's Disease) Tests
    Policy CodePolicy 0571
    Change TypeNo material changes
    Effective DateNov 9, 2001
    Last ReviewAug 11, 2023
    Next Review DateJun 13, 2024
    Key ActionObtain and document baseline and repeat audiometry when ordering dehydration (glycerol/urea) testing and limit dehydration testing to atypical presentations of Meniere's disease.
    SourceLink
    On This Page
    Coverage Criteria for Diagnostic Tests for Endolymphatic Hydrops (Meniere's Disease)Coding and Diagnostic CriteriaProvider Actions, Prior Authorization, and DocumentationBackground and RationaleDefinitions and Test DescriptionsPolicy Revision History

    Combination audiologic measures may modestly improve diagnostic accuracy but available studies are limited in size; routine use is discouraged by guideline recommendation.

    Test performance (affected ear)Sensitivity 58.3% / Specificity 66.3%
    • Baseline audiometric testing must be performed prior to administration of the osmotic agent.
    • Repeat audiometry is typically performed at 3 hours post-ingestion (and sometimes at 1 and 2 hours); test positivity: ≥10 dB improvement at 2 or more frequencies (250–2,000 Hz) or ≥12% improvement in speech discrimination.
    • Dehydration testing may cause adverse effects (headache, nausea, diarrhea, emesis, diuresis, dizziness) — weigh risks/benefits and document atypical presentation justification.
    Step Therapy

    Step Therapy Requirements

    No step therapy or prior authorization step-therapy requirements are described for the diagnostic tests discussed in the source excerpts.

    • Provider should follow standard preauthorization processes where explicitly recommended (e.g., IV-Gd MRI) but there are no step-therapy sequences required for testing.
    Documentation Required

    Documentation Required for IV-Gd MRI

    Document the clinical correlation and rationale when ordering IV-Gd inner-ear MRI to support medical necessity and prior-authorization requests.

    • Include: presenting symptoms, laterality, audiovestibular test results (audiometry, ECoG, VEMP, caloric testing as available), prior interventions, and how MRI results will change management.
    • If MRI is being used because other evaluations are inconclusive or to evaluate atypical/secondary/embryopathic EH, state this explicitly in the request.
    Note

    Clinical Evidence and Study Findings

    Clinical studies summarized in the policy provide context for the diagnostic performance and limitations of ECoG, multi-frequency tympanometry (MFT), and IV-Gd MRI; include these data in clinical decision-making and documentation when relevant.

    • Use study limitations (sample size, lack of controls, timing relative to attacks, disease duration) to justify or temper the use of tests in documentation.
    • Do not rely on ECoG or MFT as routine definitive diagnostic tests; reference guideline recommendations against routine use of ECoG for establishing MD diagnosis.
    Note

    Operational Notes / Not Applicable Content

    Not applicable: the source excerpts do not specify discrete authorization triggers, billing denial codes, or exact stepwise authorization workflows beyond the IV-Gd MRI recommendation and the medical necessity criteria for dehydration testing.

    • Providers should follow payer-specific prior authorization procedures when recommended and include the documentation elements noted above.
    • Routine testing (ECoG, vestibular testing) is discouraged for establishing diagnosis per guidelines and may not be supported without clear clinical justification.
    oVEMP roleEngages utricular and saccular afferents; may be useful for assessment, monitoring progression, and identifying active ear in bilateral disease
    VEMP — definition and role (alternative)
    Measurement typesIncludes ocular (oVEMP) and cervical (cVEMP) recordings assessing thresholds, latencies, and amplitudes
    Diagnostic performanceAbnormalities reported in MD but overlap with controls limits use as sole diagnostic test
    Study findingIn Johnson et al. (2016), oVEMP and cVEMP abnormalities found in MD patients with cochlear hydrops, but overlap reduced standalone diagnostic reliability
    VHIT — definition and typical findings
    DefinitionVideo head impulse test (VHIT) — a test of semicircular canal function using high-speed video to measure VOR gain and detect corrective saccades.
    Typical VHIT findings in MDMany MD patients have normal VHIT despite abnormal caloric testing; abnormal VHIT defined by presence of saccades or reduced gain (<0.78 horizontal, <0.64 vertical)
    Clinical implicationNormal VHIT outside crisis may help distinguish MD from other inner ear diseases
    ECoG — definition and meta-analysis performance
    DefinitionElectrocochleography (ECoG) — measurement of cochlear potentials including summating potential (SP) and action potential (AP) used to calculate SP/AP ratio.
    Meta-analysis performanceSP/AP amplitude ratio sensitivity ~47.6% and specificity ~83.8% (Ayub et al. 2019)
    Clinical guidanceLimited sensitivity and moderate specificity; guidelines advise against routine ordering solely to establish MD diagnosis
    IV-Gd inner-ear MRI — definition and variable sensitivity/specificity
    DefinitionIntravenous gadolinium (IV-Gd) inner-ear MRI — hydrops-protocol MRI after IV gadolinium to visualize endolymphatic hydrops via endolymph/perilymph contrast.
    Variable accuracyReported sensitivity and specificity vary by study, timing, and technique (example pooled report: 69% sensitivity / 83% specificity noted in evidence summary)
    LimitationsReproducibility, grading methods, inclusion criteria, and early/subtle disease detection are inconsistent across studies; correlation with audiovestibular tests recommended
    Frequency-specific electrocochleography (ECoG) — technique and measures
    TechniqueFrequency-specific extratympanic ECoG measures action potential (AP) latency and traveling wave time in addition to SP/AP ratio.
    Measured parametersAP latency, basilar membrane traveling wave time, and SP/AP ratio are recorded to evaluate cochlear mechanics hypothesized to reflect hydrops
    Study findingsConway et al. (2021) found no significant difference in AP latency or AP/SP ratio between MD and non-MD groups, limiting clinical utility
    Multi-frequency tympanometry (MFT) — test description and physiologic rationale
    Test descriptionMulti-frequency tympanometry (MFT) — in-office tympanometry using 2-kHz probe tones measuring conductance (Y width) proposed to reflect cochlear pressure variations.
    Physiologic rationaleY width at 2-kHz may increase with cochlear pressure changes related to endolymphatic hydrops, providing a noninvasive surrogate measure
    Performance and limitationde Jong et al. (2023) found mean Y width higher in affected ears but high false-positive rate; authors did not support standardized use